Meeting Banner
Abstract #3890

Preclinical in Vitro and in vivo Assessment of a Novel Graphene Based MRI Contrast Agent

Shruti kanakia1, Jimmy Toussaint1, Sayan Mullick Chowdhury1, Tanuf Tembulkar1, Terry Button2, Kenneth Shroyer3, William Moore2, Balaji Sitharaman1

1Biomedical Engineering, Stony Brook Univeristy, Stony Brook, NY, United States; 2Radiology, Stony Brook Univeristy, Stony Brook, NY, United States; 3Pathology, Stony Brook Univeristy, Stony Brook, NY, United States


We report pre-clinical in vitro and in vivo small animal studies of a novel graphene-based MRI CA. The formulation called GNP-Dex consists of monodisperse graphene nanoplatelets (GNPs; small disc-shaped graphene nanoparticles with diameter ~40 nm and thickness ~3-4 nm), intercalated with manganese Mn2+ ions, and water-solubilized with dextran. The results show that the GNP-Dex formulation is safe (LD50 > 500 mg/kg). At potential therapeutic doses (≤100 mg/kg), they show no nephrotoxicity and are more efficacious than clinical MRI CAs Magnevist and Ablavar. The results indicate that GNP-Dex show potential for development as high performance clinical T1 MRI CA.